Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1985 May;75(5):1591–1599. doi: 10.1172/JCI111865

Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition.

S R Hanson, L A Harker, T D Bjornsson
PMCID: PMC425500  PMID: 3923041

Abstract

To resolve questions of drug actions, efficacy, and interactions for platelet-modifying agents used clinically, we have compared the relative capacities and mechanisms of aspirin, dipyridamole, sulfinpyrazone, and dazoxiben to prevent arterial thromboembolism in a baboon model. In 136 studies the agents were given twice daily by oral administration both singly and in combination. The antithrombotic efficacy of a given therapy was determined by its capacity to interrupt steady-state platelet utilization induced by thrombogenic arteriovenous cannulae. When given alone, dipyridamole and sulfinpyrazone reduced the rate at which platelets were utilized by thrombus formation in a dose-dependent manner with essentially complete interruption by dipyridamole at 10 mg/kg per d. In contrast, neither aspirin (2-100 mg/kg per d) nor dazoxiben (20-100 mg/kg per d) decreased cannula platelet consumption detectably despite the striking reduction in the capacity of platelets to produce thromboxane B2. However, aspirin, but not dazoxiben, potentiated the antithrombotic effects of dipyridamole and sulfinpyrazone in a dose-dependent fashion without changing the pharmacokinetics for any of the agents. Complete potentiation required aspirin at 20 mg/kg per d to be given with each dose of dipyridamole. Because dazoxiben's blockade of platelet thromboxane A2 production was not associated with antithrombotic potentiation, and because complete potentiation by aspirin required a dose that fully inhibited vascular production of prostaglandin I2 (PGI2), we conclude that aspirin's potentiating effect on dipyridamole is independent of PGI2 production or inhibition of thromboxane A2 formation. In addition, because frequent repeated and synchronous dosing of aspirin was necessary, aspirin's potentiating effects appear to be produced by mechanism(s) unrelated to its potent, irreversible inhibition of platelet cyclooxygenase.

Full text

PDF
1591

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ali M., McDonald J. W. Effects of sulfinpyrazone on platelet prostaglandin synthesis and platelet release of serotonin. J Lab Clin Med. 1977 Apr;89(4):868–875. [PubMed] [Google Scholar]
  2. Baur H. R., VanTassel R. A., Pierach C. A., Gobel F. L. Effects of sulfinpyrazone on early graft closure after myocardial revascularization. Am J Cardiol. 1982 Feb 1;49(2):420–424. doi: 10.1016/0002-9149(82)90519-7. [DOI] [PubMed] [Google Scholar]
  3. Bjornsson T. D., Wolfram K. M., Routledge P. A., Shand D. G. High-performance liquid chromatographic analysis of sulfinpyrazone and its metabolites in biological fluids. J Chromatogr. 1980 Mar 14;181(3-4):417–425. doi: 10.1016/s0378-4347(00)81144-5. [DOI] [PubMed] [Google Scholar]
  4. Cham B. E., Ross-Lee L., Bochner F., Imhoff D. M. Measurement and pharmacokinetics of acetylsalicylic acid by a novel high performance liquid chromatographic assay. Ther Drug Monit. 1980;2(4):365–372. [PubMed] [Google Scholar]
  5. Chesebro J. H., Clements I. P., Fuster V., Elveback L. R., Smith H. C., Bardsley W. T., Frye R. L., Holmes D. R., Jr, Vlietstra R. E., Pluth J. R. A platelet-inhibitor-drug trial in coronary-artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. N Engl J Med. 1982 Jul 8;307(2):73–78. doi: 10.1056/NEJM198207083070201. [DOI] [PubMed] [Google Scholar]
  6. Chesebro J. H., Fuster V., Elveback L. R., Clements I. P., Smith H. C., Holmes D. R., Jr, Bardsley W. T., Pluth J. R., Wallace R. B., Puga F. J. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N Engl J Med. 1984 Jan 26;310(4):209–214. doi: 10.1056/NEJM198401263100401. [DOI] [PubMed] [Google Scholar]
  7. Croset M., Lagarde M. Stereospecific inhibition of PGH2-induced platelet aggregation by lipoxygenase products of icosaenoic acids. Biochem Biophys Res Commun. 1983 May 16;112(3):878–883. doi: 10.1016/0006-291x(83)91699-6. [DOI] [PubMed] [Google Scholar]
  8. Crutchley D. J., Ryan U. S., Ryan J. W. Effects of aspirin and dipyridamole on the degradation of adenosine diphosphate by cultured cells derived from bovine pulmonary artery. J Clin Invest. 1980 Jul;66(1):29–35. doi: 10.1172/JCI109831. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. DORNHORST A. C. The interpretation of red cell survival curves. Blood. 1951 Dec;6(12):1284–1292. [PubMed] [Google Scholar]
  10. Dale J., Myhre E., Storstein O., Stormorken H., Efskind L. Prevention of arterial thromboembolism with acetylsalicylic acid. A controlled clinical study in patients with aortic ball valves. Am Heart J. 1977 Jul;94(1):101–111. doi: 10.1016/s0002-8703(77)80351-7. [DOI] [PubMed] [Google Scholar]
  11. Dieterle W., Faigle J. W., Mory H., Richter W. J., Theobald W. Biotransformation and pharmacokinetics of sulfinpyrazone (Anturan) in man. Eur J Clin Pharmacol. 1975 Dec 19;9(2-3):135–145. doi: 10.1007/BF00614010. [DOI] [PubMed] [Google Scholar]
  12. Donadio J. V., Jr, Anderson C. F., Mitchell J. C., 3rd, Holley K. E., Ilstrup D. M., Fuster V., Chesebro J. H. Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy. N Engl J Med. 1984 May 31;310(22):1421–1426. doi: 10.1056/NEJM198405313102203. [DOI] [PubMed] [Google Scholar]
  13. Fuster V., Chesebro J. H., Frye R. L., Elveback L. R. Platelet survival and the development of coronary artery disease in the young adult: effects of cigarette smoking, strong family history and medical therapy. Circulation. 1981 Mar;63(3):546–551. doi: 10.1161/01.cir.63.3.546. [DOI] [PubMed] [Google Scholar]
  14. Goldman M. D., Simpson D., Hawker R. J., Norcott H. C., McCollum C. N. Aspirin and dipyridamole reduce platelet deposition on prosthetic femoro-popliteal grafts in man. Ann Surg. 1983 Dec;198(6):713–716. doi: 10.1097/00000658-198312000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gresele P., Zoja C., Deckmyn H., Arnout J., Vermylen J., Verstraete M. Dipyridamole inhibits platelet aggregation in whole blood. Thromb Haemost. 1983 Dec 30;50(4):852–856. [PubMed] [Google Scholar]
  16. Harker L. A. 189. Prog Hemost Thromb. 1978;4:321–347. [PubMed] [Google Scholar]
  17. Harker L. A., Hanson S. R. Experimental arterial thromboembolism in baboons. Mechanism, quantitation, and pharmacologic prevention. J Clin Invest. 1979 Aug;64(2):559–560. doi: 10.1172/JCI109494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Harker L. A., Harlan J. M., Ross R. Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. Circ Res. 1983 Dec;53(6):731–739. doi: 10.1161/01.res.53.6.731. [DOI] [PubMed] [Google Scholar]
  19. Harker L. A., Slichter S. J. Platelet and fibrinogen consumption in man. N Engl J Med. 1972 Nov 16;287(20):999–1005. doi: 10.1056/NEJM197211162872001. [DOI] [PubMed] [Google Scholar]
  20. Harker L. A., Slichter S. J., Sauvage L. R. Platelet consumption by arterial prostheses: the effects of endothelialization and pharmacologic inhibition of platelet function. Ann Surg. 1977 Nov;186(5):594–601. doi: 10.1097/00000658-197711000-00009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Harker L. A., Slichter S. J. Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves. N Engl J Med. 1970 Dec 10;283(24):1302–1305. doi: 10.1056/NEJM197012102832402. [DOI] [PubMed] [Google Scholar]
  22. Harter H. R., Burch J. W., Majerus P. W., Stanford N., Delmez J. A., Anderson C. B., Weerts C. A. Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. N Engl J Med. 1979 Sep 13;301(11):577–579. doi: 10.1056/NEJM197909133011103. [DOI] [PubMed] [Google Scholar]
  23. Kaegi A., Pineo G. F., Shimizu A., Trivedi H., Hirsh J., Gent M. Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone. N Engl J Med. 1974 Feb 7;290(6):304–306. doi: 10.1056/NEJM197402072900604. [DOI] [PubMed] [Google Scholar]
  24. Klabunde R. E. Dipyridamole inhibition of adenosine metabolism in human blood. Eur J Pharmacol. 1983 Sep 16;93(1-2):21–26. doi: 10.1016/0014-2999(83)90026-2. [DOI] [PubMed] [Google Scholar]
  25. Lewis H. D., Jr, Davis J. W., Archibald D. G., Steinke W. E., Smitherman T. C., Doherty J. E., 3rd, Schnaper H. W., LeWinter M. M., Linares E., Pouget J. M. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983 Aug 18;309(7):396–403. doi: 10.1056/NEJM198308183090703. [DOI] [PubMed] [Google Scholar]
  26. Lewy R. I., Wiener L., Walinsky P., Lefer A. M., Silver M. J., Smith J. B. Thromboxane release during pacing-induced angina pectoris: possible vasoconstrictor influence on the coronary vasculature. Circulation. 1980 Jun;61(6):1165–1171. doi: 10.1161/01.cir.61.6.1165. [DOI] [PubMed] [Google Scholar]
  27. Lorenz R. L., Schacky C. V., Weber M., Meister W., Kotzur J., Reichardt B., Theisen K., Weber P. C. Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily). Effects on platelet aggregation and thromboxane formation. Lancet. 1984 Jun 9;1(8389):1261–1264. doi: 10.1016/s0140-6736(84)92446-2. [DOI] [PubMed] [Google Scholar]
  28. Louie S., Gurewich V. The antithrombotic effect of aspirin and dipyridamole in relation to prostaglandin synthesis. Thromb Res. 1983 May 15;30(4):323–335. doi: 10.1016/0049-3848(83)90224-4. [DOI] [PubMed] [Google Scholar]
  29. Mahony C., Cox J. L., Bjornsson T. D. Plasma dipyridamole concentrations after two different dosage regimens in patients. J Clin Pharmacol. 1983 Feb-Mar;23(2-3):123–126. doi: 10.1002/j.1552-4604.1983.tb02714.x. [DOI] [PubMed] [Google Scholar]
  30. Mahony C., Wolfram K. M., Cocchetto D. M., Bjornsson T. D. Dipyridamol kinetics. Clin Pharmacol Ther. 1982 Mar;31(3):330–338. doi: 10.1038/clpt.1982.42. [DOI] [PubMed] [Google Scholar]
  31. Mahony C., Wolfram K. M., Nash P. V., Bjornsson T. D. Kinetics and metabolism of sulfinpyrazone. Clin Pharmacol Ther. 1983 Apr;33(4):491–497. doi: 10.1038/clpt.1983.67. [DOI] [PubMed] [Google Scholar]
  32. Majerus P. W. Arachidonate metabolism in vascular disorders. J Clin Invest. 1983 Nov;72(5):1521–1525. doi: 10.1172/JCI111110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Malpass T. W., Hanson S. R., Savage B., Hessel E. A., 2nd, Harker L. A. Prevention of acquired transient defect in platelet plug formation by infused prostacyclin. Blood. 1981 Apr;57(4):736–740. [PubMed] [Google Scholar]
  34. Moncada S., Korbut R. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet. 1978 Jun 17;1(8077):1286–1289. doi: 10.1016/s0140-6736(78)91269-2. [DOI] [PubMed] [Google Scholar]
  35. Murphy E. A., Francis M. E. The estimation of blood platelet survival. II. The multiple hit model. Thromb Diath Haemorrh. 1971;25(1):53–80. [PubMed] [Google Scholar]
  36. Pay G. F., Wallis R. B., Zelaschi D. The effect of sulphinpyrazone and its metabolites on platelet function in vitro and ex vivo. Haemostasis. 1981;10(3):165–175. doi: 10.1159/000214400. [DOI] [PubMed] [Google Scholar]
  37. Pinckard R. N., Hawkins D., Farr R. S. In vitro acetylation of plasma proteins, enzymes and DNA by aspirin. Nature. 1968 Jul 6;219(5149):68–69. doi: 10.1038/219068a0. [DOI] [PubMed] [Google Scholar]
  38. Rao A. K., Walsh P. N. Acquired qualitative platelet disorders. Clin Haematol. 1983 Feb;12(1):201–238. [PubMed] [Google Scholar]
  39. Reidenberg M. M. The binding of drugs to plasma proteins from patients with poor renal function. Clin Pharmacokinet. 1976;1(2):121–125. doi: 10.2165/00003088-197601020-00003. [DOI] [PubMed] [Google Scholar]
  40. Ritchie J. L., Harker L. A. Platelet and fibrinogen survival in coronary atherosclerosis. Response to medical and surgical therapy. Am J Cardiol. 1977 Apr;39(4):595–598. doi: 10.1016/s0002-9149(77)80171-9. [DOI] [PubMed] [Google Scholar]
  41. Roth G. J., Majerus P. W. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest. 1975 Sep;56(3):624–632. doi: 10.1172/JCI108132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Sattin A., Rall T. W. The effect of adenosine and adenine nucleotides on the cyclic adenosine 3', 5'-phosphate content of guinea pig cerebral cortex slices. Mol Pharmacol. 1970 Jan;6(1):13–23. [PubMed] [Google Scholar]
  43. Slichter S. J., Harker L. A. Preparation and storage of platelet concentrates. II. Storage variables influencing platelet viability and function. Br J Haematol. 1976 Nov;34(3):403–419. doi: 10.1111/j.1365-2141.1976.tb03587.x. [DOI] [PubMed] [Google Scholar]
  44. Steele P., Battock D., Genton E. Effects of clofibrate and sulfinpyrazone on platelet survival time in coronary artery disease. Circulation. 1975 Sep;52(3):473–476. doi: 10.1161/01.cir.52.3.473. [DOI] [PubMed] [Google Scholar]
  45. Steele P., Carroll J., Overfield D., Genton E. Effect of sulfinpyrazone on platelet survival time in patients with transient cerebral ischemic attacks. Stroke. 1977 May-Jun;8(3):396–398. doi: 10.1161/01.str.8.3.396. [DOI] [PubMed] [Google Scholar]
  46. Steele P., Rainwater J. Favorable effect of sulfinpyrazone on thromboembolism in patients with rheumatic heart disease. Circulation. 1980 Sep;62(3):462–465. doi: 10.1161/01.cir.62.3.462. [DOI] [PubMed] [Google Scholar]
  47. Steele P., Rainwater J., Vogel R., Genton E. Platelet-suppressant therapy in patients with coronary artery disease. JAMA. 1978 Jul 21;240(3):228–231. [PubMed] [Google Scholar]
  48. Steele P., Rainwater J., Vogel R. Platelet suppressant therapy in patients with prosthetic cardiac valves. Relationship of clinical effectiveness to alteration of platelet survival time. Circulation. 1979 Oct;60(4):910–913. doi: 10.1161/01.cir.60.4.910. [DOI] [PubMed] [Google Scholar]
  49. Sullivan J. M., Harken D. E., Gorlin R. Pharmacologic control of thromboembolic complications of cardiac-valve replacement. N Engl J Med. 1971 Jun 24;284(25):1391–1394. doi: 10.1056/NEJM197106242842501. [DOI] [PubMed] [Google Scholar]
  50. Weily H. S., Steele P. P., Davies H., Pappas G., Genton E. Platelet survival in patients with substitute heart valves. N Engl J Med. 1974 Mar 7;290(10):534–537. doi: 10.1056/NEJM197403072901002. [DOI] [PubMed] [Google Scholar]
  51. Wolfram K. M., Bjornsson T. D. High-performance liquid chromatographic analysis of dipyridamole in plasma and whole blood. J Chromatogr. 1980 Jul 11;183(1):57–64. doi: 10.1016/s0378-4347(00)81398-5. [DOI] [PubMed] [Google Scholar]
  52. de Gaetano G., Cerletti C., Bertelè V. Pharmacology of antiplatelet drugs and clinical trials on thrombosis prevention: a difficult link. Lancet. 1982 Oct 30;2(8305):974–977. doi: 10.1016/s0140-6736(82)90168-4. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES